At the cellular level, HPPDC nanoparticles successfully overcame drug resistant in breast cancer through multiple mechanisms including CD44-mediated cellular internalization, efficient intracellular drug release, and notably suppressed P-gp and COX-2 expressions. This evidence concerns the gene PTGS2 and breast carcinoma.